Skip to main content
Home
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
      • Specialties
        • Vaccines & Infectious Diseases
        • Ophthalmology
        • Clinical Neuroscience
        • Rare Disease
        • Cell & Gene Therapy
        • Government
      • Additional Specialties
        • Hematology
        • Oncology
        • Maternal & Child Health
        • Medical Devices
      • Clinical Services
        • Biostatistics
        • Clinical Data Management
        • Clinical Research Services
        • Clinical Trial Management
        • Global Regulatory Affairs
        • Pharmacovigilance & Medical Monitoring
    • Veridix - Tech & AI
      • eClinical Platform
        • EDC
        • Decentralized Clinical Trials
        • Health Navigator
        • RTSM
        • eCOA / ePRO
      • AI Agents
        • Biostats and Analysis Agent
        • Data Management Agent
        • Document Authoring
      • GlobalTrace
      • Analytics & Reporting
        • Clinical Pipelines
        • VERA
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Locations
    • Contact Us

Breadcrumb

  1. Emmes Group

Umbilical Cord Blood Transplantation in Adults: Results of the Prospective Cord Blood Transplantation (COBLT)

Go back to Resources

Umbilical Cord Blood Transplantation in Adults: Results of the Prospective Cord Blood Transplantation (COBLT)

Authors:

Secondary:

Volume:

Pagination:

URL:

Keywords:

Abstract:

Go back to Resources

The Influence of Immunomodulatory Diets on Transplant Success and Complications

Go back to Resources

The Influence of Immunomodulatory Diets on Transplant Success and Complications

Authors:

Secondary:

Volume:

Pagination:

URL:

Keywords:

Abstract:

Go back to Resources

Safety and Immunogenicity of MVA.HIVA by 3 Different Routes

Go back to Resources

Safety and Immunogenicity of MVA.HIVA by 3 Different Routes

Authors:

Secondary:

Location:

Go back to Resources

Risk Factors Associated with the Incidence of Age-Related Macular Degeneration in The Age-Related Eye Disease Study (AREDS) AREDS Report No. 19

Go back to Resources

Risk Factors Associated with the Incidence of Age-Related Macular Degeneration in The Age-Related Eye Disease Study (AREDS) AREDS Report No. 19

Authors:

Secondary:

Volume:

Pagination:

URL:

Keywords:

Abstract:

Go back to Resources

Review of Hemostatic Agents Used in Dentistry

Go back to Resources

Review of Hemostatic Agents Used in Dentistry

Authors:

Secondary:

Volume:

Pagination:

URL:

Keywords:

Go back to Resources

C-Reactive Protein and Homocysteine are Associated With Dietary and Behavioral Risk Factors for Age-Related Macular Degeneration

Go back to Resources

C-Reactive Protein and Homocysteine are Associated With Dietary and Behavioral Risk Factors for Age-Related Macular Degeneration

Authors:

Secondary:

Volume:

Pagination:

URL:

Keywords:

Abstract:

Go back to Resources

Baseline Patient Characteristics in the PKC-DRS2 Trial: The Effect of The PKC-b Inhibitor Ruboxistaurin on Moderate Visual Loss

Go back to Resources

Baseline Patient Characteristics in the PKC-DRS2 Trial: The Effect of The PKC-b Inhibitor Ruboxistaurin on Moderate Visual Loss

Authors:

Secondary:

Location:

URL:

Go back to Resources

A Rabbit Model for Assessing the Ocular Barriers to the Transscleral Delivery of Triamcinolone Acetonide

Go back to Resources

A Rabbit Model for Assessing the Ocular Barriers to the Transscleral Delivery of Triamcinolone Acetonide

Authors:

Secondary:

Volume:

Pagination:

URL:

Keywords:

Abstract:

Go back to Resources

A Phase I Study of 4 Live, Recombinant Human Cytomegalovirus Towne/Toledo Chimeric Vaccines

Go back to Resources

A Phase I Study of 4 Live, Recombinant Human Cytomegalovirus Towne/Toledo Chimeric Vaccines

Authors:

Secondary:

Volume:

Pagination:

URL:

Keywords:

Abstract:

Go back to Resources

A Novel and Efficient Site Selection Process for a Large Multi-Center Trial

Go back to Resources

A Novel and Efficient Site Selection Process for a Large Multi-Center Trial

Authors:

Secondary:

Location:

Go back to Resources

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 150
  • Page 151
  • Page 152
  • Page 153
  • Current page 154
  • Page 155
  • Page 156
  • Page 157
  • Page 158
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to
Emmes Group

Delivering Global Health
Impact Through People,
Science and Technology

Main navigation
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
    • Veridix - Tech & AI
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Locations
    • Contact Us

Copyright ©, The Emmes Company, LLC

Footer
  • Cookie Policy
  • External Privacy Notice
  • FCOI
  • Emmes EU-U.S. Data Privacy Framework
  • Purchasing Terms and Conditions